This A2AR-mediated control of neuroinflammation is argued to be critical for the neuroprotection afforded by A2AR blockade in PD since the inhibition of microglial function has been shown to be sufficient to decrease the dopaminergic neurodegeneration characteristic of PD. This evidence concerns the gene ADORA2A and Parkinson disease.